Merz Aesthetics, the world’s largest dedicated medical aesthetics business, has made an investment in Acorn Biolabs by leading its Series A funding round. Acorn Biolabs is a personalized regenerative medicine company with offices in Toronto, Canada and Los Angeles. Acorn Biolabs offers the world’s first non-invasive, follicle-based, stem cell cryopreservation service and is developing treatments made from a client’s own cells. Terms were not disclosed.

“Merz Aesthetics is at the forefront of the emerging field of regenerative aesthetics, which seeks to stimulate the body’s own systems to repair and restore the structure and integrity of aging skin. We are looking to invest in opportunities that lie at the intersection of regenerative aesthetics and personalized medicine and our investment in Acorn Biolabs directly aligns with this strategy,” said Jon Parrish, PhD, chief corporate development officer at Merz Aesthetics.

Read more at Merz Aesthetics >>